MIRA Pharmaceuticals, Inc.
MIRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $413 | $496 | $314 | $861 |
| G&A Expenses | $0 | $1,050 | $1,491 | $1,576 |
| SG&A Expenses | $904 | $1,050 | $1,491 | $1,576 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,317 | $1,546 | $1,805 | $2,438 |
| Operating Income | -$1,317 | -$1,546 | -$1,805 | -$2,438 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $179 | $8 | $21 | $38 |
| Pre-Tax Income | -$1,138 | -$1,538 | -$1,784 | -$2,400 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22,694 | -$1,538 | -$1,784 | -$2,400 |
| % Margin | – | – | – | – |
| EPS | -1.18 | -0.091 | -0.11 | -0.16 |
| % Growth | -1,203.9% | 17.7% | 31.3% | – |
| EPS Diluted | -1.18 | -0.091 | -0.11 | -0.16 |
| Weighted Avg Shares Out | 19,275 | 16,986 | 16,645 | 15,444 |
| Weighted Avg Shares Out Dil | 19,275 | 16,986 | 16,645 | 15,444 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $8 | $21 | $38 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1,138 | -$1,546 | -$1,805 | -$2,438 |
| % Margin | – | – | – | – |